Pargyline Hydrochloride | CAS#306-07-0 | MAO inhibitor

MedKoo Cat#: 318456 | Name: Pargyline Hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pargyline hydrochloride is a monoamine oxidase inhibitor with antihypertensive properties. Pargyline selectively inhibits MAO type B, an enzyme catalyzing the oxidative deamination and inactivation of certain catecholamines, such as norepinephrine and dopamine, within the presynaptic nerve terminals. By inhibiting the metabolism of these biogenic amines in the brain, pargyline increases their concentration and binding to postsynaptic receptors.

Chemical Structure

Pargyline Hydrochloride

CAS#306-07-0

Theoretical Analysis

MedKoo Cat#: 318456

Name: Pargyline Hydrochloride

CAS#: 306-07-0

Chemical Formula: C11H14ClN

Exact Mass: 0.0000

Molecular Weight: 195.69

Elemental Analysis: C, 67.51; H, 7.21; Cl, 18.12; N, 7.16

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350.00
200mg	USD 650.00
500mg	USD 950.00
1g	USD 1,450.00
2g	USD 2,250.00
5g	USD 2,950.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Pargyline Hydrochloride; N-benzyl-N-methylprop-2-yn-1-amine hydrochloride; Eutonyl-ten; N-Methyl-N-propargylbenzylamine hydrochloride; Pargyline HCl; Pargyline;

IUPAC/Chemical Name

N-benzyl-N-methylprop-2-yn-1-amine;hydrochloride

InChi Key

BCXCABRDBBWWGY-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H

SMILES Code

CN(CC#C)CC1=CC=CC=C1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B.

In vitro activity:

The purpose of this study was to investigate the effects of the MAO inhibitors, pargyline and tranylcypromine on cell survival in human prostate carcinoma (LNCaP-LN3) cells. The proliferation of cells exposed to pargyline decreased in a dose- and time-dependent manner, while tranylcypromine-treated cells showed the opposite results. Treatment with pargyline significantly induced cell cycle arrest at the G1 phase compared to the control and tranylcypromine-treated cells. In addition, pargyline induced an increase in the cell death rate by promoting apoptosis; however, tranylcypromine had no effect on LNCaP-LN3 cells. Reference: Oncol Rep. 2013 Oct;30(4):1587-92. https://pubmed.ncbi.nlm.nih.gov/23900512/

In vivo activity:

SCID mice were injected subcutaneously with LNCap cells. Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression. The results showed that LSD1 expression was up-regulated when PCa progressed to Castration Resistant Prostate Cancer (CRPC). Pargyline reduced LNCap cells migration and invasion ability, and inhibited the process of EMT by up-regulating expression of E-cadherin, and down-regulating expressions of N-cadherin and Vimentin in vitro and in vivo. Although, Pargyline did not change the level of AR, it reduced PSA expression both in vitro and in vivo. Furthermore, Pargyline delayed prostate cancer transition from androgen-dependent to androgen-independent state (CRPC). Reference: Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. https://pubmed.ncbi.nlm.nih.gov/26435505/

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	102.20
	DMSO	30.3	155.01
	Ethanol	34.5	176.30
	PBS (pH 7.2)	5.0	25.55
	Water	69.5	355.15

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 195.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92. doi: 10.3892/or.2013.2635. Epub 2013 Jul 24. PMID: 23900512; PMCID: PMC3810355. 2. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 3. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.

In vitro protocol:

In vivo protocol:

1. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 2. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.

1: Kwieciński A, Nowak P. Effect of prenatal manganese intoxication on [(3)H]glucose uptake in the brain of rats lesioned as neonates with 6-hydroxydopamine. Pharmacol Rep. 2009 May-Jun;61(3):558-63. doi: 10.1016/s1734-1140(09)70099-4. PMID: 19605956. 2: Pedersen K, Simonsen M, Østergaard SD, Munk OL, Rosa-Neto P, Olsen AK, Jensen SB, Møller A, Cumming P. Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO- inhibition. Neuroimage. 2007 Mar;35(1):38-46. doi: 10.1016/j.neuroimage.2006.11.038. Epub 2007 Jan 16. PMID: 17223363. 3: Ruhoğlu O, Ozdemir Z, Caliş U, Gümüşel B, Bilgin AA. Synthesis of and pharmacological studies on the antidepressant and anticonvulsant activities of some 1,3,5-trisubstituted pyrazolines. Arzneimittelforschung. 2005;55(8):431-6. PMID: 16149709. 4: Matsunaga K, Sato T, Shuto H, Tsuruta Y, Suemaru K, Gomita Y, Oishi R. Inhibition of neuronal dopamine uptake by some antiallergic drugs. Eur J Pharmacol. 1998 Jun 5;350(2-3):165-9. doi: 10.1016/s0014-2999(98)00253-2. PMID: 9696404. 5: Sato T, Suemaru K, Matsunaga K, Hamaoka S, Gomita Y, Oishi R. Potentiation of L-dopa-induced behavioral excitement by histamine H1-receptor antagonists in mice. Jpn J Pharmacol. 1996 May;71(1):81-4. doi: 10.1254/jjp.71.81. PMID: 8791174. 6: Honkanen A, Chrapusta SJ, Karoum F, Korpi ER. Alterations in dopamine metabolism by intraperitoneal ethanol in rats selected for high and low ethanol preference: a 3-methoxytyramine study. Alcohol. 1994 Jul-Aug;11(4):323-8. doi: 10.1016/0741-8329(94)90099-x. PMID: 7945987. 7: Bilgin AA, Palaska E, Sunal R. Studies on the synthesis and antidepressant activity of some 1-thiocarbamoyl-3,5-diphenyl-2-pyrazolines. Arzneimittelforschung. 1993 Oct;43(10):1041-4. PMID: 8267665. 8: AboulWafa OM, el-Metwalli MA. Benzo[b]thiophenes, II: Novel benzo[b]thienylhydrazine and 1,3,4-oxadiazole derivatives as potential antidepressant agents. Arch Pharm (Weinheim). 1992 Sep;325(9):603-8. doi: 10.1002/ardp.19923250915. PMID: 1444765. 9: Phebus LA, Roush ME, Clemens JA. Effect of direct and indirect dopamine agonists on brain extracellular ascorbate levels in the striatum and nucleus accumbens of awake rats. Life Sci. 1990;47(15):1317-23. doi: 10.1016/0024-3205(90)90195-w. PMID: 1978214. 10: Durden DA, Nguyen TV, Boulton AA. Kinetics of intraventricularly injected trace amines and their deuterated isotopomers. Neurochem Res. 1988 Oct;13(10):943-50. doi: 10.1007/BF00970766. PMID: 3216952. 11: Itoh Y, Oishi R, Nishibori M, Saeki K. Phencyclidine and the dynamics of mouse brain histamine. J Pharmacol Exp Ther. 1985 Dec;235(3):788-92. PMID: 4078733. 12: Itoh Y, Nishibori M, Oishi R, Saeki K. Changes in histamine metabolism in the mouse hypothalamus induced by acute administration of ethanol. J Neurochem. 1985 Dec;45(6):1880-5. doi: 10.1111/j.1471-4159.1985.tb10547.x. PMID: 4056796. 13: Whitton PS, Oresković D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacol. 1985 Mar;37(3):199-200. doi: 10.1111/j.2042-7158.1985.tb05040.x. PMID: 2580072. 14: Nishibori M, Oishi R, Saeki K. Histamine turnover in the brain of different mammalian species: implications for neuronal histamine half-life. J Neurochem. 1984 Dec;43(6):1544-9. doi: 10.1111/j.1471-4159.1984.tb06076.x. PMID: 6491668. 15: Osamu I. A new metabolically trapped agent by brain monoamine oxidase: N-methyl labeled (14C) N-methylphenylethylamine (14C-MPEA). Eur J Nucl Med. 1983;8(9):385-8. doi: 10.1007/BF00253211. PMID: 6628439. 16: Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S. Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. doi: 10.1001/archpsyc.1982.04290050023006. PMID: 7092487. 17: Lowe MC. Hepatotoxicity of pargyline hydrochloride. Proc West Pharmacol Soc. 1978;21:215. PMID: 693498. 18: González Martínez JL, Saiz I, Velasco A, García de Jalón PD. Efecto del fosfato de iproniazida y clorhidrato de pargilina sobre el consumo de oxígeno, glucosa y fosforilización oxidativa mitocondrial de cerebro de rata in vitro [Effect of iproniazid phosphate and pargyline hydrochloride on oxygen consumption, glucose and mitochondrial oxidative phosphorylation of the rat brain in vitro]. Arch Farmacol Toxicol. 1977 Dec;3(3):259-66. Spanish. PMID: 613983. 19: Felmus MT, Patten BM, Hart A, Martinez C. Catecholamine-induced muscle weakness. Arch Neurol. 1977 May;34(5):280-4. doi: 10.1001/archneur.1977.00500170034005. PMID: 857783. 20: Chopra YM, Dandiya PC. On the mechanism of reversal of reserpine action by pargyline hydrochloride. Arch Int Pharmacodyn Ther. 1969 Sep;181(1):47-56. PMID: 5350784.